Blocking CCR5 in cancer affects the glycocalyx pri
Post# of 157735
(Total Views: 789)
Posted On: 08/22/2025 10:36:05 PM
Blocking CCR5 in cancer affects the glycocalyx primarily through its interaction with heparan sulfate proteoglycans (HSPGs), which are key components of the glycocalyx. Inhibiting CCR5 disrupts pro-tumorigenic signaling pathways that are often coordinated with glycocalyx components, influencing cancer cell survival, metastasis, and metabolism.
In layman's terms; Leronlimab will crack the armor, and allow the T-Cells, and Macrophages to get their foot in the door.
Coreceptor functions of cell surface heparan sulfate proteoglycans - PMC https://share.google/gtKKNuEa0tg0bThoF
Heparan sulfate signaling in cancer - PMC https://share.google/PxCf9GOEyQzH8i2XE
In layman's terms; Leronlimab will crack the armor, and allow the T-Cells, and Macrophages to get their foot in the door.
Coreceptor functions of cell surface heparan sulfate proteoglycans - PMC https://share.google/gtKKNuEa0tg0bThoF
Heparan sulfate signaling in cancer - PMC https://share.google/PxCf9GOEyQzH8i2XE
(18)
(0)